Application of immunosignatures to the assessment of Alzheimer's disease

Annals of Neurology

Volumn 70, Issue 2, 2011, Pages 286-295

  Restrepo, Lucas ^a,b   Stafford, Phillip ^a   Magee, D Mitch ^a   Johnston, Stephen Albert ^a,b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; EPITOPE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN ANTIBODY; TAU PROTEIN; TAU PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOREACTIVITY; IMMUNOSIGNATURE; MICROARRAY ANALYSIS; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MICROARRAY; SEQUENCE ANALYSIS; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; HUMANS; IMMUNOASSAY; MICE; MICE, TRANSGENIC; MICROARRAY ANALYSIS; PEPTIDES; TAU PROTEINS;

EID: 80051532205     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22405     Document Type: Article

References (37)

1. Brookmeyer R, Grey S, Kawas CH,. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-1342. (Pubitemid 28402270)
2. Chui H, Lee AE,. Clinical criteria for dementia subtypes. In:, Qizilbash N, Schneider L, Brodaty H, et al., eds. Evidence-based dementia practice. Oxford: Blackwell Science, 2002: 106-119.
3. Kawas CH,. Early Alzheimer's disease. N Engl J Med 2003; 349: 1056-1063. (Pubitemid 37087621)
4. Petersen R, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 760.
5. Wimo A, Winblad B,. Health economical aspects of Alzheimer disease. Psychogeriatrics. 2001; 1: 189-193.
6. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma proteins. Nat Med 2007; 13: 1359-1362. (Pubitemid 350073592)
7. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2: 864-870. (Pubitemid 26296755)
8. Wyss-Coray T,. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006; 12: 1005-1015. (Pubitemid 44353380)
9. Baril L, Nicolas L, Croisile B, et al. Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects. Neurosci Lett 2004; 355: 226-230. (Pubitemid 38368744)
10. Dodel R, Hampel H, Depboylu C, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002; 52: 253-256. (Pubitemid 34810613)
11. Du Y, Dodel R, Hampel H, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001; 57: 801-805. (Pubitemid 32845498)
12. Du Y, Wei X, Dodel R, et al. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 2003; 126: 1935-1939. (Pubitemid 37059433)
13. Friedland R, Tedesco JM, Wilson AC, et al. Antibodies to potato virus Y bind the amyloid {beta} peptide: immuno-histochemical and NMR studies. J Biol Chem 2008; 283: 22550-22556.
14. Gaskin F, Kingsley BS, Fu SM,. Autoantibodies to neurofibrillary tangles and brain tissue in Alzheimer's disease. Epstein-Barr virus-transformed antibody-producing cell lines. J Exp Med 1987; 165: 245-250. (Pubitemid 17223685)
15. Lopez O, Rabin BS, Huff FJ, et al. Serum autoantibodies in patients with Alzheimer's disease and vascular dementia and in nondemented control subjects. Stroke 1992; 23: 1078-1083.
16. Moir R, Tseitlin KA, Soscia S, et al. Autoantibodies to redox-modified oligomeric A{beta} are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem 2005; 280: 17458-17463. (Pubitemid 41389217)
17. Mruthini S, Buccafusco JJ, Hill WD, et al. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding and RAGE peptides. Neurobiol Aging 2004; 25: 1023-1032. (Pubitemid 38798064)
18. Nath A, Hall E, Tuzova M, et al. Autoantibodies to amyloid β-peptide are increased in Alzheimer's disease patients and Aβ antibodies can enhance Aβ neurotoxicity. Neuromol Med 2003; 3: 29-39.
19. O'Nuallain B, Hrncic R, Wall JS, et al. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol 2006; 176: 7071-7078. (Pubitemid 43787888)
20. Patton R, Kalback WM, Esh CL, et al. Amiloid-β peptide remnants in AN-1792-immunized Alzheimer's disease patients. Am J Pathol 2006; 169: 1048-1063. (Pubitemid 44411966)
21. Rosenmann H, Meiner Z, Geylis V, et al. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci Lett 2006; 410: 90-93. (Pubitemid 44709405)
22. Tan E, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997; 40: 1601-1611. (Pubitemid 27426153)
23. Boltz K, Gonzalez-Moa MJ, Stafford P, et al. Peptide microarrays for carbohydrate recognition. Analyst 2009; 134: 650-652.
24. Legutki J, Magee DM, Stafford P, Johnston SA,. A general method for characterization of humoral immunity induced by a vaccine or infection. Vaccine 2010; 28: 4529-4537.
25. Morales Betanzos C, Gonzalez-Moa MJ, Boltz KW, et al. Bacterial glycoprofiling by using random sequence peptide microarrays. Chembiochem 2009; 10: 877-888.
26. Williams B, Diehnelt CW, Belcher P, et al. Creating protein affinity reagents by combining peptide ligands on synthetic DNA scaffolds. J Am Chem Soc 2009; 131: 17233-17241.
27. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537.
28. Stafford P, Brun M,. Three methods for optimization of cross-laboratory and cross-platform microarray expression data. Nucleic Acids Res 2007; 35: e72.
29. Kim S, Dougherty ER, Barrera J, et al. Strong feature sets from small samples. J Comput Biol 2002; 9: 127-146. (Pubitemid 34264289)
30. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57: 289-300.
31. Götz J, Ittner LM,. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 2008; 9: 532-543.
32. Qu B, Rosenberg RN, Li L, et al. Gene vaccination to bias the immune response to amyloid-peptide as therapy for Alzheimer disease. Arch Neurol 2004; 61: 1859-1864. (Pubitemid 39612946)
33. Qu B, Xiang Q, Li L, et al. Aβ42 gene vaccine prevents Aβ42 deposition in brain of double transgenic mice. J Neurol Sci 2007; 260: 204-213. (Pubitemid 47212229)
34. Larkin M, Blackshields G, Brown NP, et al. ClustalW and ClustalX version 2. Bioinformatics 2007; 23: 2947-2948.
35. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-489. (Pubitemid 36444329)
36. Reddy MM, Wilson R, Wilson J, et al. Identification of candidate IgG biomarkers of Alzheimer's disease via combinatorial library screening. Cell 2011; 144: 132-142.
37. Lindstrom TM, Robinson WH,. Fishing for biomarkers with antigen mimics. Cell 2011; 144: 13-15.